Preview : Published ahead of advance online publication Clonal evolution in hematologic malignancies and therapeutic implications

This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. NPG are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

[1]  X. Estivill,et al.  Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis , 2013, Leukemia.

[2]  T. Chevassut,et al.  The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.

[3]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[4]  Rona S. Gertner,et al.  Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells , 2013, Nature.

[5]  R. Geffers,et al.  U-2932: two clones in one cell line, a tool for the study of clonal evolution , 2013, Leukemia.

[6]  T. Cezard,et al.  Exome sequencing in tracking clonal evolution in multiple myeloma following therapy , 2013, Leukemia.

[7]  Zachary D. Smith,et al.  DNA methylation: roles in mammalian development , 2013, Nature Reviews Genetics.

[8]  Carlos López-Otín,et al.  The evolutionary biography of chronic lymphocytic leukemia , 2013, Nature Genetics.

[9]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[10]  A. Ferrando,et al.  Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL , 2013, Nature Medicine.

[11]  O. Elemento,et al.  Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity , 2013, PLoS genetics.

[12]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[13]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[14]  R. Dalla‐Favera,et al.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.

[15]  V. Carlton,et al.  Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. , 2012, Blood.

[16]  Catherine J. Wu.  CLL clonal heterogeneity: an ecology of competing subpopulations. , 2012, Blood.

[17]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.

[18]  C. Swanton.  Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[19]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[20]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[21]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[22]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[23]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[24]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[25]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[26]  B. Seliger,et al.  Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation , 2012, Transplantation.

[27]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[28]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[29]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[30]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[31]  Huanming Yang,et al.  Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm , 2012, Cell.

[32]  Huanming Yang,et al.  Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.

[33]  R. Kuiper,et al.  The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution , 2012, PLoS genetics.

[34]  S. Kopetz,et al.  Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. , 2012, Cancer research.

[35]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[36]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[37]  H. Fine,et al.  Many tumors in one: a daunting therapeutic prospect. , 2011, Cancer cell.

[38]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[39]  L. Conlin,et al.  Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia. , 2011, Cancer genetics.

[40]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[41]  J. Finke,et al.  Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  Hanna Göransson,et al.  Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia , 2011, Haematologica.

[43]  L. Loeb,et al.  Human cancers express mutator phenotypes: origin, consequences and targeting , 2011, Nature Reviews Cancer.

[44]  F. Sigaux,et al.  Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse , 2011 .

[45]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[46]  Hans Clevers,et al.  The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.

[47]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[48]  A. Oudenaarden,et al.  Cellular Decision Making and Biological Noise: From Microbes to Mammals , 2011, Cell.

[49]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[50]  R. Kefford,et al.  Targeting BRAF for patients with melanoma , 2010, British Journal of Cancer.

[51]  G. Wahl,et al.  Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures , 2010, Proceedings of the National Academy of Sciences.

[52]  T. Haferlach,et al.  Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[54]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[55]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[56]  S. Armstrong,et al.  NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[57]  C. Maley,et al.  The role of genetic diversity in cancer. , 2010, The Journal of clinical investigation.

[58]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[59]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[60]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[61]  J. Salk.  Clonal evolution in cancer , 2010 .

[62]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[63]  N. Chiorazzi,et al.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. , 2009, Blood.

[64]  A. Rosenwald,et al.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies. , 2009, Blood.

[65]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Pier Paolo Di Fiore,et al.  The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells , 2009, Cell.

[67]  R. Weinberg,et al.  Cancer stem cells: mirage or reality? , 2009, Nature Medicine.

[68]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[69]  Stephen Yip,et al.  MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.

[70]  G. Maira,et al.  Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution , 2009, Oncogene.

[71]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[72]  Paul Marjoram,et al.  Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers , 2009, Proceedings of the National Academy of Sciences.

[73]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[74]  B. Sleckman,et al.  Collateral Damage from Antigen Receptor Gene Diversification , 2008, Cell.

[75]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[76]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[77]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Stratton,et al.  Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing , 2008, Proceedings of the National Academy of Sciences.

[79]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[80]  T. Vincent,et al.  An evolutionary model for initiation, promotion, and progression in carcinogenesis. , 2008, International journal of oncology.

[81]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[82]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[83]  Axel Benner,et al.  Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival , 2007, Haematologica.

[84]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[85]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[86]  Nobuyoshi Shimizu,et al.  Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. , 2006, Cancer research.

[87]  A. Neri,et al.  IgV gene intraclonal diversification and clonal evolution in B‐cell chronic lymphocytic leukaemia , 2006, British journal of haematology.

[88]  Carissa A. Sanchez,et al.  Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.

[89]  B. Kerem,et al.  The molecular basis of common and rare fragile sites. , 2006, Cancer letters.

[90]  Alfonso Martinez Arias,et al.  Filtering transcriptional noise during development: concepts and mechanisms , 2006, Nature Reviews Genetics.

[91]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[92]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[93]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[94]  Carissa A. Sanchez,et al.  Selectively Advantageous Mutations and Hitchhikers in Neoplasms , 2004, Cancer Research.

[95]  A. Tefferi,et al.  Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. , 2004, Leukemia research.

[96]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[97]  M. Nowak,et al.  Evolutionary Dynamics of Biological Games , 2004, Science.

[98]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[99]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[100]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[101]  David Jablonski,et al.  Lessons from the past: Evolutionary impacts of mass extinctions , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[102]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[103]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[104]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[105]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[106]  C. Bloomfield,et al.  Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). , 1992, Blood.

[107]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[108]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[109]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[110]  J. Dick,et al.  Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. , 1987, Cancer research.

[111]  V. Ling,et al.  Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[112]  I. Fidler,et al.  Tumor heterogeneity and the biology of cancer invasion and metastasis. , 1978, Cancer research.

[113]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.